Stop, Collaborate… and Effectively Manage Dry Eye Disease

Diagnostic and treatment devices team up to provide disruptive DED solutions leading to improved tear film quality and quantity

by Brooke Herron

Topcon (Singapore) and Espansione Group (Bologna, Italy) are collaborating to bring innovative solutions to dry eye disease patients in Southeast Asia and beyond — and at APACRS 2023, attendees can experience these devices first-hand…

Dry eye disease (DED) causes a significant burden worldwide … but even more so in Asia, where it enjoys a 20% prevalence.1 This high DED incidence means that reliable diagnostics and effective treatments are required to improve symptoms and quality of life. As a result, Topcon and Espansione Group have teamed up to knock out DED in Southeast Asia with an innovative (and disruptive) diagnostic and treatment device combination: MYAH and eye-light®.

As a globally-oriented business, Topcon develops solutions that solve major challenges in eye health: A prime example of this mission is illustrated by MYAH, a unique and multifunctional device for myopia and DED diagnosis and management. Meanwhile, Espansione Group is driven to create new paradigms in ophthalmology by providing the best medical technologies, as evidenced by eyelight®, which includes cutting-edge, light-based treatment for safe and effective patient care. Topcon will now be the sole distributor of Espansione Group’s full portfolio in Southeast Asia.

Set your sights on this powerful DED combo

Perhaps best known for its myopia management capabilities, Topcon’s MYAH is an all-in-one device that offers optical biometry, corneal topography, pupillometry and contact lens fitting. However, this evolving platform also provides the necessary tools needed to diagnose and manage DED, too. There are four tear-related acquisition modes available on the MYAH: blink assessment (BLINK), Meibomian gland imaging (MEIB), tear meniscus height measurement (TMH) and non-invasive tear break-up time (TBT), which is a fundamental measurement in the diagnosis and management of ocular surface disease. Together, these tools provide physicians with a reliable DED diagnosis and insights into managing this multifactorial disease.

Once a diagnosis is made, Espansione Group’s eye-light® steps in to deliver highly effective and completely noninvasive therapies that significantly relieve DED symptoms for longterm management. As an all-in-one treatment powerhouse for ocular surface health, eye-light® features two of the company’s core technologies: Light Modulation® Low-level Light Therapy (LM® LLLT) and Optimal Power Energy® Intense Pulsed Light (OPE® IPL). Both light-based technologies have proven safety and efficacy in numerous clinical studies — including more than 30 scientific papers on LM® LLLT technology in the past few years, alone. In fact, a 2023 paper2 found that “LLLT significantly improved tear film production and stability along with ocular discomfort symptoms in patients with DED owing to MGD.”

Considered to be a groundbreaking partnership, this alliance promises to raise the bar in the management of dry eye and many more ocular surface conditions (e.g., chalazion, blepharitis, Sjögren’s Syndrome and Demodex) in Southeast Asia and beyond — making the final score win-win for both physicians and patients. Indeed, when used together, these complementary devices — MYAH and eye-light® — can offer powerful, synergistic solutions for comprehensive patient care, as well as opportunities for eye care professionals to build and grow their practice.

To learn more, visit the Topcon booth #A34 from June 8-10 at APACRS 2023

References

1. Cai Y. Wei J, Zhou J, Zou W. Prevalence and Incidence of Dry Eye Disease in Asia: A Systematic Review and Meta-Analysis. Ophthalmic Res. 2022;65(6):647-658.

2. Giannaccare G, Vaccaro S, Pellegrini M, et al. Serial Sessions of a Novel Low-Level Light Therapy Device for Home Treatment of Dry Eye Disease. Ophthalmol Ther. 2023;12(1):459468.